Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~Distal subungual onychomycosis of the great toenail, affecting at least ≥25 to ≤75% of nail.~Positive culture for dermatophytes and positive KOH.~Nail ≤ 3 mm thick at the distal end.~At least ≥ 2 mm of the proximal end of the great toenail must be free of infection.~Subjects must be able to swallow tablets.~Women of childbearing potential and males must use acceptable birth control methods throughout the study.~Key Exclusion Criteria:~Presence of subungual hematoma or melanonychia.~Presence of dermatophytoma/nail streaks and severe onychorrhexis.~Significant dystrophy or anatomic abnormalities of the great toenail.~Presence of any other infections of the foot.~Evidence of clinically significant major organ disease.~Poorly controlled diabetes mellitus.~Onychomycosis involving more than 8 toe nails.~Recent use of systemic antifungal therapy.~Recent of any topical antifungal nail therapy.~Recent use of systemic corticosteroid therapy.~Recent use of immunosuppressive medication.~History of prolonged QT intervals.~Known human immunodeficiency virus (HIV) infection.~Known significant renal or hepatic impairment.~Known history of intolerance or hypersensitivity to azole antifungal drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low dose 12-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
- Low dose 24-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
- High dose 12-week (Type: EXPERIMENTAL): 4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
- High dose 24-week (Type: EXPERIMENTAL): 4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).